Loading...
XSHE
002390
Market cap776mUSD
Jul 10, Last price  
2.78CNY
1D
2.58%
1Q
-14.72%
Jan 2017
-71.89%
IPO
-41.35%
Name

Guizhou Xinbang Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002390 chart
P/E
44.93
P/S
0.96
EPS
0.06
Div Yield, %
2.21%
Shrs. gr., 5y
3.67%
Rev. gr., 5y
-0.83%
Revenues
5.61b
-7.04%
173,328,000217,754,000274,743,000336,685,856318,627,651361,865,000447,572,062569,487,9222,476,183,0594,179,756,0985,157,031,7746,002,471,0306,580,278,9176,655,063,5765,845,621,5246,471,866,3346,350,025,8266,460,841,3146,032,262,0515,607,378,761
Net income
120m
+18.65%
17,451,00029,911,00033,614,00046,689,48937,757,39346,079,00047,828,99540,237,322144,770,449174,379,440246,012,801319,383,504-1,296,605,446236,301,517173,521,479272,869,192224,374,025287,232,802101,381,627120,285,770
CFO
752m
+18.49%
7,346,00032,486,00024,861,00041,753,0002,501,000-39,867,000-36,464,000-21,338,000-198,597,000217,402,000-198,585,000201,743,000-218,563,000886,328,000742,112,000457,972,000590,797,000790,618,000634,969,000752,363,205
Dividend
Sep 26, 20250.03 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Guizhou Xinbang Pharmaceutical Co., Ltd. specializes in the entire process of researching, developing, manufacturing, and distributing both traditional Chinese herbal medicines and cutting-edge biological pharmaceuticals. The company's operations span across China and international markets. Its diverse range of pharmaceutical offerings covers treatments for cardiovascular and cerebrovascular conditions, digestive system disorders, endocrine imbalances, tumor and immune regulation, blood system ailments, rheumatism and rheumatoid diseases, and urinary tract issues. Additionally, it provides antipyretic analgesics, cold medications, gynecological therapies, and anti-infective drugs. Founded in 1995, the firm's headquarters are situated in Guiyang, China.
URL
http://www.xinbang.com/
IPO date
Apr 16, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT